WNT7A Human

Wingless-Type MMTV Integration Site Family, Member 7A Human Recombinant
Shipped with Ice Packs
In Stock

Description

Molecular Structure and Biochemical Properties

WNT7A is a cysteine-rich, lipid-modified protein with the following key features:

PropertyDetails
Amino Acid Length341 amino acids (UniProt: O00755)
Molecular Weight~38 kDa (non-glycosylated, E. coli-derived) ; 40–55 kDa (glycosylated)
DomainsN-terminal signal peptide, conserved Wnt lipid-binding motif
Post-Translational ModificationsPalmitoleoylation (essential for receptor binding)
Expression SystemsE. coli (non-glycosylated) , HEK293 (glycosylated)

Structural studies reveal that WNT7A binds to Frizzled (FZD) receptors and co-receptors like WLS (Wntless) and CALR (calreticulin) for secretion and signaling . The crystal structure (PDB: 8TZO) shows a phospholipid-mediated interaction with WLS, critical for its stability and transport .

Biological Functions

WNT7A regulates diverse developmental and pathological processes:

Embryonic Development

  • Guides anterior-posterior axis formation in the female reproductive tract .

  • Essential for limb patterning, skeletal morphogenesis, and Müllerian duct development .

  • Maintains neural stem cell self-renewal and synaptic formation in the CNS .

Adult Tissue Homeostasis

  • Modulates uterine smooth muscle function and responds to sex steroid hormones .

  • Inhibits interleukin-1β (IL-1β)-induced catabolic gene expression (e.g., MMP1, MMP13) in articular chondrocytes, protecting against osteoarthritis .

Disease Mechanisms

DiseaseRole of WNT7A
CancerDual role: Promotes HNSCC, lung, and ovarian cancer ; suppresses NSCLC .
Osteoarthritis (OA)Downregulated in OA cartilage; inversely correlates with MMP levels .
Genetic DisordersMutations linked to Fuhrmann syndrome and limb malformations .

In Oncology

  • Pro-Tumorigenic Effects:

    • Upregulated in head and neck squamous cell carcinoma (HNSCC), activating Wnt/β-catenin signaling to drive proliferation .

    • Enhances immune evasion by suppressing MHC-I expression, limiting CD8+ T-cell infiltration .

  • Therapeutic Targeting:

    • Blocking WNT7A with small molecules (e.g., 1365-0109) restores MHC-I levels and synergizes with anti-PD-1 therapy in murine models .

In Regenerative Medicine

  • Intraarticular Wnt7a injections reduce cartilage degradation in osteoarthritis models by inhibiting MMP activity .

  • Promotes myogenic stem cell engraftment and muscle regeneration via FZD7 signaling .

Therapeutic Development

  • Agonists: Potential for treating OA and neurodegenerative disorders .

  • Antagonists: Investigated in cancers with WNT7A overexpression (e.g., HNSCC) .

Diagnostic Biomarkers

  • Reduced WNT7A mRNA and protein levels correlate with OA severity .

  • WNT7A mutations serve as diagnostic markers for rare skeletal dysplasias .

Key Challenges and Future Directions

  • Resolve context-dependent roles in cancer (pro- vs. anti-tumorigenic) .

  • Optimize delivery systems for WNT7A-based therapies to overcome poor solubility .

  • Validate clinical efficacy in ongoing trials targeting Wnt pathways.

Product Specs

Introduction
WNT7A, also known as Wingless-Type MMTV Integration Site Family, Member 7A, is a member of the WNT gene family. This family comprises structurally related genes that encode secreted signaling proteins. These proteins are implicated in oncogenesis and various developmental processes, such as regulating cell fate and patterning during embryogenesis. WNT7A plays a crucial role in developing the anterior-posterior axis in the female reproductive tract. It is also essential for uterine smooth muscle patterning and maintaining adult uterine function. Mutations in WNT7A have been linked to Fuhrmann and Al-Awadi Raas-Rothschild Schinzel phocomelia syndromes.
Description
Recombinant human WNT7A, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 341 amino acids (residues 32-349). It has a molecular mass of 38 kDa. WNT7A is fused to a 23 amino acid His-tag at the N-terminus and purified using proprietary chromatographic techniques.
Physical Appearance
A sterile, colorless solution.
Formulation
The WNT7A protein solution has a concentration of 1 mg/ml and contains 20 mM Tris-HCl buffer (pH 8.0), 10% glycerol, and 0.4 M Urea.
Stability
**Store at 4°C if the entire vial will be used within 2-4 weeks. For longer storage, freeze at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid multiple freeze-thaw cycles.**
Purity
The purity is greater than 85.0% as determined by SDS-PAGE.
Synonyms
Wingless-Type MMTV Integration Site Family, Member 7A, Proto-Oncogene Wnt7a Protein, Protein Wnt-7a.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSLGASIIC NKIPGLAPRQ RAICQSRPDA IIVIGEGSQM GLDECQFQFR NGRWNCSALG ERTVFGKELK VGSREAAFTY AIIAAGVAHA ITAACTQGNL SDCGCDKEKQ GQYHRDEGWK WGGCSADIRY GIGFAKVFVD AREIKQNART LMNLHNNEAG RKILEENMKL ECKCHGVSGS CTTKTCWTTL PQFRELGYVL KDKYNEAVHV EPVRASRNKR PTFLKIKKPL SYRKPMDTDL VYIEKSPNYC EEDPVTGSVG TQGRACNKTA PQASGCDLMC CGRGYNTHQY ARVWQCNCKF HWCCYVKCNT CSERTEMYTC K.

Product Science Overview

Gene Family and Function

The WNT gene family is known for its role in the Wnt signaling pathway, which is essential for regulating cell fate, proliferation, migration, and patterning during embryonic development. WNT7A, in particular, functions as a ligand for members of the frizzled family of seven transmembrane receptors, operating within the canonical Wnt/β-catenin signaling pathway . This pathway is vital for numerous developmental processes, including dorsal-ventral patterning during limb development, skeleton development, and urogenital tract development .

Role in Development and Disease

WNT7A is involved in the development of the anterior-posterior axis in the female reproductive tract and plays a critical role in uterine smooth muscle patterning and maintenance of adult uterine function . Mutations in the WNT7A gene are associated with several congenital disorders, such as Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndromes . These conditions are characterized by limb malformations and other developmental abnormalities.

Research and Applications

Research on WNT7A has shown its potential in targeting Wnt signaling to block angiogenesis and glucose uptake in brain tumors . This highlights the therapeutic potential of modulating Wnt signaling pathways in cancer treatment. Additionally, recombinant WNT7A proteins are used in various research applications to study their role in development and disease.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.